Mary Beth Farrell, Kathy S. Thomas, Eleanor Mantel, Jessica Settle
177Lu-PSMA-617 (brand name Pluvicto), is a prostate-specific membrane antigen (PSMA) targeted ligand therapy. PSMA is overexpressed in most prostate adenocarcinomas and this property can be exploited therapeutically. It is prescribed for patients diagnosed with hormone-resistant metastatic prostate